What is the 13F Pro Quality Score for LLY?

13F Pro ranks ELI LILLY & Co (LLY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LLY's current score at https://13fpro.ai/company/LLY (free sign-up required for the full ranking).

Which hedge funds own the most LLY stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LLY include LILLY ENDOWMENT, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/LLY as soon as new 13F filings post.

Where does 13F Pro source LLY data?

All ELI LILLY & Co fundamentals and ownership data come directly from SEC EDGAR. ELI LILLY & Co files with the SEC under CIK 59478. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LLY in?

ELI LILLY & Co (LLY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives LLY's revenue?

Per ELI LILLY & Co's latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Cardiometabolic Health ($18.4B, +61% YoY); Oncology ($2.6B, +6% YoY); Immunology ($1.4B, +13% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/LLY.

What are LLY's largest expenses?

ELI LILLY & Co's latest 10-Q reports these as the largest expense items: Marketing, selling, and administrative ($3.4B, +25% YoY); Research and development ($3.8B, +14% YoY); Cost of sales ($3.3B, +34% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is LLY research updated on 13F Pro?

LLY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ELI LILLY & Co(LLY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmega

Institutional-grade research for retail investors

SEC EDGAR: CIK 59478 LLY stock profile & AI dashboard →

13F Pro Quality Score

87.5/100

Rank #2 of 2,961 stocksTOP 1%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

92.7/100

Profitability

94.6/100

Balance Sheet

96.8/100

Earnings Quality

62.4/100

Free Cash Flow

88.0/100

Institutional Flow

67.6/100

Revenue Scale

98.1/100

Dilution Risk

57.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why LLY Scores 88/100

exact factor attribution · 2026-09-11

LLY's composite is driven by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.5 pts

93th pct

Scale

+7.2 pts

98th pct

Profitability

+6.7 pts

95th pct

Free cash flow

+5.7 pts

88th pct

Capital efficiency

+4.7 pts

97th pct

Earnings growth

+2.2 pts

94th pct

Earnings quality

+1.2 pts

62th pct

Institutional flow

+0.9 pts

68th pct

Shareholder dilution

+0.4 pts

58th pct

Latest change (2026-08-05): 89 → 86 · ↓ Revenue growth 90→82; ↓ Free cash flow 85→76

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

LLY Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ELI LILLY & Co (LLY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LLY at 87.5/100 on a 32-signal composite quality model, placing it at rank #2 of 2,961 stocks — the top 1% of the AI-ranked universe. LLY scores in the top quartile across revenue scale (98.1), balance sheet strength (96.8), profitability (94.6). Based on the latest XBRL financial filings (Q2 2026), ELI LILLY & Co reports quarterly revenue of $23.0B, net income of $7.1B, an operating margin of 40.3%. Top institutional holders of LLY by reported 13-F value include LILLY ENDOWMENT, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LLY trades on the NYSE exchange and files with the SEC under CIK 59478. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LLY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ELI LILLY & Co directly from SEC EDGAR. ELI LILLY & Co's 13F Pro composite quality score has ranged between 67 and 88 since 2021, currently 87.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about ELI LILLY & Co

Quirks, history, and lore behind LLY — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. pharmaceutical company · mega-cap · listed on the NYSE · headquartered in Indiana.
2
The Numbers
Annual revenue surpassed $40 billion in recent years, and its market cap rocketed past $700 billion — making it one of the most valuable healthcare companies on Earth.
3
The History
Founded in 1876 by a Civil War veteran-turned-chemist, it was among the first drug companies to mass-produce insulin in the 1920s, partnering with the scientists who discovered it.
4
The Secret
It quietly became a neuroscience and oncology powerhouse, with blockbuster drugs treating everything from diabetes to cancer to Alzheimer's driving its explosive growth.
5
The Lore
Its GLP-1 weight-loss and diabetes drugs triggered a global shortage so severe that pharmacies worldwide couldn't keep up — patients were rationing doses and governments took notice.
6
The Giveaway
Mounjaro. Zepbound. Trulicity. The Indiana drugmaker whose tirzepatide made the whole world want to talk about their waistline.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving LLY's Business? Latest 10-Q Breakdown

AI-extracted from ELI LILLY & Co's 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Eli Lilly's Q2 revenue surged 48% YoY to $23.0B, driven by Mounjaro and Zepbound incretin medicines which accounted for 65% of H1 2026 revenue, with net income up 25% despite $2.8B in acquired IPR&D charges.

Biggest Revenue Drivers

Cardiometabolic Health$18.4B+61% YoY

Strong demand for Mounjaro and Zepbound, partially offset by lower realized prices due to pricing agreements and Mounjaro's addition to China's NRDL.

Oncology$2.6B+6% YoY

Verzenio growth moderated; Other oncology products increased volume.

Biggest Revenue Drivers

Total revenue: $23.0B+48% YoY

Cardiometabolic Health$18.4B+61% YoY

Strong demand for Mounjaro and Zepbound, partially offset by lower realized prices due to pricing agreements and Mounjaro's addition to China's NRDL.

Oncology$2.6B+6% YoY

Verzenio growth moderated; Other oncology products increased volume.

Immunology$1.4B+13% YoY

Taltz and Other immunology products grew modestly.

Neuroscience and Other$0.6B

Includes neuroscience portfolio and other product lines.

Largest Expense Items

Marketing, selling, and administrative$3.4B+25% YoY

Increased promotional efforts supporting ongoing and planned product launches.

Research and development$3.8B+14% YoY

Continued investments in early and late-stage portfolio development.

Cost of sales$3.3B+34% YoY

Gross margin improved to 85.8% despite volume-driven COGS increase due to better production efficiency.

Margins: Gross margin as a percentage of revenue expanded 150 basis points to 85.8%, driven by improved cost of production and favorable product mix, partially offset by lower realized prices from pricing negotiations and international market pressures.

Watch Items from the Filing

Three acquisitions (Centessa, Kelonia, Ventyx) and subsequent July 2026 acquisitions totaled ~$13.3B YTD with contingent milestones up to $5.3B; pending AtaiBeckley acquisition adds ~$2.8B exposure.
Medicare GLP-1 Bridge program and Medicaid access launched July 2026 with unknown uptake; IRA price controls effective 2028 for Trulicity and Verzenio; pricing reforms may reduce future revenue.
Generic ANDA filings received for Verzenio (Cipla, June 2026) and tirzepatide products (multiple companies, July 2026) before patent expiration; patent infringement litigation filed June-July 2026.
Total debt increased $12.4B to $54.9B (May 2026 issuance of $9.0B) to fund acquisitions and commercial paper repayment; capital expenditures expected to be meaningfully higher near-term for manufacturing expansion.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$23.0B

Net Income

Q2 2026

$7.1B

Operating Margin

Q2 2026

40.3%

ROIC

Q2 2026

41.7%

D/E Ratio

Q2 2026

1.62

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+44.7% YoY

$65.18BFY 2025

FY22 $28.54BFY23 $34.12BFY24 $45.04BFY25 $65.18B

Net Income

+94.9% YoY

$20.64BFY 2025

FY22 $6.24BFY23 $5.24BFY24 $10.59BFY25 $20.64B

EPS (Diluted)

+96.0% YoY

$22.95FY 2025

FY22 $6.90FY23 $5.80FY24 $11.71FY25 $22.95

Total Assets

+42.9% YoY

$112.48BFY 2025

FY22 $49.49BFY23 $64.01BFY24 $78.71BFY25 $112.48B

Total Debt

+26.3% YoY

$42.50BFY 2025

FY22 $16.24BFY23 $25.23BFY24 $33.64BFY25 $42.50B

Op. Cash Flow

+90.7% YoY

$16.81BFY 2025

FY22 $7.59BFY23 $4.24BFY24 $8.82BFY25 $16.81B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$65.18B +44.7%	$45.04B +32.0%	$34.12B +19.6%	$28.54B +0.8%	$28.32B +15.4%	$24.54B
Net Income	$20.64B +94.9%	$10.59B +102.1%	$5.24B -16.1%	$6.24B +11.9%	$5.58B -9.9%	$6.19B
EPS (Diluted)	$22.95 +96.0%	$11.71 +101.9%	$5.80 -15.9%	$6.90 +12.7%	$6.12 -9.9%	$6.79
Total Assets	$112.48B +42.9%	$78.71B +23.0%	$64.01B +29.3%	$49.49B +1.4%	$48.81B +4.7%	$46.63B
Total Debt	$42.50B +26.3%	$33.64B +33.4%	$25.23B +55.3%	$16.24B -3.8%	$16.88B +1.7%	$16.60B
Operating Cash Flow	$16.81B +90.7%	$8.82B +108.0%	$4.24B -44.1%	$7.59B +3.0%	$7.37B +13.3%	$6.50B

AI Insight: LLY Financial Trends

Revenue surged 68% from Q3 2024 to Q2 2026; debt leverage climbed sharply while equity growth lagged cash generation.

• Revenue nearly doubled: $11.4B (Q3 2024) to $23.0B (Q2 2026), driven by sustained quarterly growth acceleration.

• Net income grew 625% from $970M (Q3 2024) to $7.1B (Q2 2026), signaling strong operational leverage.

• Operating cash flow surged to $10.7B (Q2 2026), the strongest quarter on record in this dataset.

• Total debt increased 76% to $54.9B (Q2 2026) while equity rose only 133% to $33.9B, raising debt/equity ratio.

⚠ Debt/equity ratio deteriorated from 2.19x (Q3 2024) to 1.62x (Q2 2026), driven by aggressive debt issuance.

⚠ Net income and operating cash flow volatility: cash swung 228% from $1.7B (Q1 2025) to $10.7B (Q2 2026).

AI Insight: LLY Ratio Trends

Lilly's profitability remains exceptional at 42% operating margin, but momentum cooled in Q2 2026 as ROE and ROIC declined sequentially.

• Operating margin sustained above 40% for four consecutive quarters (Q4 2025–Q2 2026), demonstrating durable pricing power and scale.

• ROIC peaked at 47.9% in Q4 2025 and 47.5% in Q1 2026, then contracted to 41.7% in Q2 2026—first meaningful pullback in six quarters.

• Leverage improved sharply: D/E fell from 2.44 in Q1 2025 to 1.39 in Q1 2026, signaling disciplined capital allocation despite high debt levels.

• Net profit margin dipped 6.5pp from Q1 2026 (37.4%) to Q2 2026 (30.9%), indicating margin pressure or seasonal variance.

⚠ Q2 2026 sequential declines across ROE (94.8%→83.8%), ROA (25.4%→20.0%), and ROIC—assess if temporary or signals competitive/pricing headwinds.

⚠ D/E rebounded to 1.62 in Q2 2026 from 1.39 in Q1, erasing recent deleveraging gains; monitor debt trajectory.

Get alerted when LLY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ELI LILLY & Co including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LLY

LILLY ENDOWMENT INC
$108.4B90,376,978 sh
BlackRock, Inc.
$81.0B67,540,400 sh
VANGUARD CAPITAL MANAGEMENT LLC
$64.2B53,528,868 sh
PNC FINANCIAL SERVICES GROUP, INC.
$61.6B51,322,720 sh
STATE STREET CORP
$43.4B36,215,754 sh
FMR LLC
$34.1B28,462,475 sh
Capital Research Global Investors
$25.0B20,873,140 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$25.0B20,859,217 sh
GEODE CAPITAL MANAGEMENT, LLC
$24.3B20,310,858 sh
MORGAN STANLEY
$19.5B16,226,398 sh

Fund	Value	Shares
LILLY ENDOWMENT INC	$108.4B	90,376,978
BlackRock, Inc.	$81.0B	67,540,400
VANGUARD CAPITAL MANAGEMENT LLC	$64.2B	53,528,868
PNC FINANCIAL SERVICES GROUP, INC.	$61.6B	51,322,720
STATE STREET CORP	$43.4B	36,215,754
FMR LLC	$34.1B	28,462,475
Capital Research Global Investors	$25.0B	20,873,140
VANGUARD PORTFOLIO MANAGEMENT LLC	$25.0B	20,859,217
GEODE CAPITAL MANAGEMENT, LLC	$24.3B	20,310,858
MORGAN STANLEY	$19.5B	16,226,398

Companies Similar to LLY

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ABBV

AbbVie Inc.

AI score

Highly similar · 56 shared holders

Capital Research Global Investors Capital World Investors Capital International Investors

AMGN

AMGEN INC

AI score

Highly similar · 45 shared holders

Capital World Investors PRIMECAP MANAGEMENT CO/CA/Capital Research Global Investors

JNJ

JOHNSON & JOHNSON

AI score

Very similar · 52 shared holders

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Capital World Investors Capital Research Global Investors

NVDA

NVIDIA CORP

AI score

Very similar · 66 shared holders

Capital Research Global Investors Capital World Investors Capital International Investors

MSFT

MICROSOFT CORP

AI score

Very similar · 58 shared holders

Capital Research Global Investors Capital World Investors Capital International Investors

AVGO

Broadcom Inc.

AI score

Very similar · 66 shared holders

Capital Research Global Investors Capital World Investors Capital International Investors

ABT

ABBOTT LABORATORIES

AI score

Very similar · 48 shared holders

Capital Research Global Investors Capital International Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

AAPL

Apple Inc.

AI score

Very similar · 62 shared holders

Capital Research Global Investors Capital World Investors Capital International Investors

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LLY on your watchlist

Track score changes the day ELI LILLY & Co files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LLY a good stock to buy?

13F Pro's AI-powered analysis of ELI LILLY & Co (LLY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LLY are available on the LLY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LLY is classified as a mega company.

Which hedge funds own LLY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LLY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ELI LILLY & Co's investment landscape.